TerminatedPhase 2

Methotrexate Followed by Fludarabine in Patients With T-Cell Large Granular Lymphocytic Leukemia

Stopped: slow recruitment

Germany12 participantsStarted 2005-06

Plain-language summary

RATIONALE: Drugs used in chemotherapy, such as methotrexate and fludarabine, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. PURPOSE: This phase II trial is studying how well methotrexate works as first-line therapy and fludarabine works as second-line therapy in treating patients with T-cell large granular lymphocytic leukemia.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

DISEASE CHARACTERISTICS: * Confirmed diagnosis of T-cell large granular lymphocytic (T-LGL) leukemia * Must have concurrent anemia or neutropenia PATIENT CHARACTERISTICS: * Life expectancy ≥ 2 years * Not pregnant * Fertile patients must use effective contraception * No other malignancy * No active infection PRIOR CONCURRENT THERAPY: * No prior immunosuppressive treatment * No previous treatment with methotrexate or fludarabine

What they're measuring

Response rate

Timeframe: 12 months after inclusion in the study

Trial details

NCT IDNCT00278265

SponsorGerman CLL Study Group

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2009-12

View on ClinicalTrials.gov More T-Cell Large Granular Lymphocytic Leukemia trials